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Abstract
Objective: To identify the incidence of and risk factors for tuberculosis in people living with HIV (PLHIV).
Design: Observational, prospective cohort study.
Methods: A total of 2069 HIV-infected patients was observed between July 2007 and December 2010. The Kaplan-Meier
method was used to estimate the probability of survival free of tuberculosis, and Cox regression analysis to identify risk
factors associated with the development of tuberculosis.
Results: Survival free of tuberculosis (TB) was 91%. The incidence rate of tuberculosis was 2.8 per 100 persons/years.
Incidence of tuberculosis was higher when subjects had CD4 cell count ,200 cells/mm3; were not on antiretroviral therapy;
in those who had, a body mass index ,18.5 kg/m2, anemia (or were not tested for it), were illiterate or referred previous
tuberculosis treatment at entry into the cohort. Those not treated for latent TB infection had a much higher risk (HR = 7.9) of
tuberculosis than those with a negative tuberculin skin test (TST). Having a TST$5 mm but not being treated for latent TB
infection increased the risk of incident tuberculosis even in those with a history of previous tuberculosis.
Conclusions: Preventive actions to reduce the risk of TB in people living with HIV should include an appropriate HAART and
treatment for latent TB infection in those with TST$5 mm. The actions towards enabling rigorous implementation of
treatment of latent TB infection and targeting of PLHIV drug users both at the individual and in public health level can
reduce substantially the incidence of TB in PLHIV.
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Introduction
Tuberculosis (TB) is a major cause of morbidity and mortality
in people living with HIV (PLHIV) [1]; it can accelerate the
course of HIV infection and decrease the survival of patients
with AIDS [2].TB mortality rates are significantly higher for
PLHIV (RR = 9), and early detection reduces the chances of
mortality [3,4]. In 2008, WHO launched a strategy for
tuberculosis control with three goals (the so-called three I’s):
increased case detection, preventive therapy with isoniazid, and
the control of HIV infection with large-scale supply of
antiretroviral therapy [5].
Studies of the risks for developing tuberculosis in PLHIV have
focused mainly on clinical and laboratory factors. Studies on
socioeconomic factors and lifestyle habits of PLHIV who develop
tuberculosis are scarce in spite of strong evidence of an association
in the general population [6]. WHO in their recommendation for
collaboration between TB/HIV control, recommends early
identification of those at risk of developing TB to introduce early
intervention.
This study aimed to estimate the incidence density and
identify risk factors for TB in PLHIV receiving medical care at
two referral centers for HIV infection in Recife, the capital city
of Pernambuco, Brazil. Pernambuco is the Brazilian state with
the second highest TB mortality rates (4.0 deaths per 100,000
inhabitants per year), almost double the national rate [7].
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Methods
Study Design and Population
This is a prospective cohort study of PLHIV in routine care,
with individuals receiving medical care in two referral hospitals
(Oswaldo Cruz University Hospital and Correia Picanco Hospi-
tal), responsible for the care of about 70% of PLHIV in the state.
Treatment for TB and for HIV is distributed free of charge by the
health services, restricted to cases notified to the System of
Notification of Infectious Diseases (SINAN)/Pernambuco (PE).
Recruitment started in July 2007 and ended in June 2010. Follow
up ended in December, 2010. All individuals aged $18 years
consenting to participate and responding to a questionnaire were
included. Since our objective was to understand the incidence of
tuberculosis, patients already being treated for TB at the time of
entry into the cohort, or who developed TB during the first month
of follow-up, were excluded.
Case Ascertainment and Definition
Incident TB was identified in three ways. (i) A new
diagnosis of TB by the attending physician (according to the
Ministry of Health of Brazil guidelines, that is based on clinical
findings, direct investigation of Acid-fast bacillus –AFB -smear and
culture for M.tb [8]). (ii) Cases of TB notified to the surveillance
system (SINAN/PE) during the follow up period and ascertained
through record linkage and (iii) deaths from TB in Mortality
Information System (SIM/PE), ascertained through record
linkage. All linkage used the probabilistic linkage program
RecLinkIII [9].
Predictor Variables
We investigated biological, socioeconomic, habits and lifestyle
factors and variables related to HIV and TB. Alcohol consumption
was defined based on reported number of drinks per day,
according to the Centers for Disease Control and Prevention
[10], which classifies people into abstainers, light drinkers
(individuals who did not drink or drank up to two drinks per
day for men, and one drink per day for women) and heavy
drinkers (more than two drinks per day for men and more than
one drink per day for women). Smoking was classified into three
categories: non-smokers (individuals who had never smoked),
former smokers (those who did not smoke when entering the study
and had stopped smoking at least six months earlier) and smokers
(those who smoked at the time of study or had stopped smoking
less than six months earlier). For the multivariate Cox regression
analysis, the categories ex-smokers and never smokers were
grouped into a single category. Individuals who reported past or
current use of marijuana, cocaine or crack were classified as drugs
users.
Subjects were classified as having anemia, if the result of the
entry blood test showed hemoglobin ,12 g/dL in women and
,14 g/dL in men, according to the EuroSIDA criterion [11]. As
this test was not done in all patients, there were a considerable
numbers of missing values (22.9%); those without a test result were
treated as a third category.
CD4 cell count at baseline was categorized as $200 cells/mm3
or ,200 cells/mm3. The use of antiretroviral drugs was measured
at various points during the follow-up and at each point was
categorized as using HAART or not. The tuberculin skin test
(TST) was performed during the patients’ follow-up by the
attending clinician using their own clinical judgment. After
conducting the TST, a positive result was considered indication
for treatment of latent tuberculosis infection (LTBI) as recom-
mended by Brazilian Ministry of Health. The treatment of LTBI
consists of isoniazid, 300 mg/day for six months [12]. Since many
were not tested, and many with indication for treatment did not
receive treatment, this variable was categorized into 4 levels,
following Golub et al: not tested, tested negative (where treatment
is not recommended), tested positive (with treatment recom-
mended and done) and tested positive (treatment recommended
but not done) [13].
After agreeing to participate and signing the informed consent,
individuals were interviewed by a nursing technician who filled a
questionnaire developed for this research; this was repeated during
the follow up (ideally every six months) during their routine health
care visits.
Statistical Analysis
Follow up time for those developing tuberculosis was the time
from start of follow-up to the date of tuberculosis diagnosis,
defined as date of initiating TB treatment (confirmed by the
notification form in the SINAN/PE) or date of death in those
dying from tuberculosis before starting treatment (confirmed by
the SIM/PE). Follow-up time for those not developing tuberculosis
was the time from start of follow up until the date of death from
other causes, date of transfer to another health service not in the
study, or the date of the end of the study, 31 December 2010.
Kaplan-Meier method was used to calculate the probability of
survival free of tuberculosis, overall and stratified by study
variables. The statistical significance of differences between the
Kaplan-Meier (KM) curves was checked by log-rank test ,0.05.
Since use of HAART changed for many patients during the follow
up, this was analyzed as time-dependent variable in the Cox
regression model, allowing us to take into account changes in risk
over time. To identify factors associated with incident TB, hazard
ratios (HR) were calculated [14]. The proportional hazards
assumption was tested in the bivariate and multivariate models.
Significant variables (p#0.20) in bivariate analysis were intro-
duced one by one according to their statistical significance and
clinical and epidemiological importance in the forward multivar-
iate Cox regression model, where they remained if the p value was
,0.05. We used Schoenfeld residuals (phtest) to test for the
proportional-hazards assumption. As antiretroviral treatment did
not respect the proportional-hazard assumption, the effect of the
other variables in the multivariate model was stratified by
HAART. Data were analyzed using the software Stata 11.2
(Stata-Corp LP, College Station, TX).
Ethical Considerations
This study is part of the project which was approved by the
Ethics Committee of Federal University of Pernambuco (CEP/
CCS/UFPE 254/05).
Results
The ‘‘Clinical-epidemiological study of co-infection tuberculo-
sis/HIV in Recife’’ cohort consisted of 2362 PLHIV. Those who
were receiving TB treatment at entry or during the first month of
follow up (293–12.4%) were excluded in this analysis. The
remaining 2069 patients were followed up for the study reported
here: 147 (7.1%) patients developed TB; 144 were reported to
SINAN/PE and the other three died before treatment started and
had TB as the cause of death in the death certificate in SIM. Of
the remaining 1922, 96 died and the death certificate registered at
SIM did not mention TB, 8 transferred out and 1818 were alive
and without TB at the end of the study.
The individual mean follow up time was just over 2.5 years
(928.7 days). The total person-years at risk was 5259, and the
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incidence rate of TB was 2.8 per 100 person-years. Figure 1 shows
the Kaplan-Meier probability of survival free of tuberculosis: 91%
by the end of follow-up.
Tables 1 and 2 present the frequency distribution of the
exposure variables. Demographic, socioeconomic and lifestyle
factors are presented in table 1, and clinical/laboratory/treatment
factors related to general health, to HIV, and to TB in table 2. The
HR, 95% CI and the p-value for the bivariate association between
each studied factor and incidence of TB; and the p-value for the
proportional-hazards assumption. Most (61%) of the patients were
male, 298 (14.5%) of the patients did not live in the metropolitan
region of Recife, 11.2% were illiterate and 31.3% lived in families
where the monthly income of the head of the family was less than
one minimum wage (on average 170dollarsover the study period).
Heavy drinking was reported by 11.4% of all patients; past or
current use of marijuana, cocaine or crack was reported by 27.4%
and most patients in the cohort (54.9%) were either smokers (29%)
or ex-smokers (25.9%). Table 2 shows that a total of 1635 (79.3%)
patients were already on antiretroviral therapy at entry into the
cohort and 1 in 5 reported a previous history of tuberculosis. As for
latent tuberculosis infection, only 58% were tested: 43% tested
negative, 15% tested positive and should have received treatment
(but only half did) and the remaining 42% were not tested. In the
Cox regression bivariate analysis, the proportional-hazards
assumption test identified one variable which didn’t have
proportional hazards during the follow up: use of antiretroviral
treatment time-dependent, and to address this we stratified the
Cox regression model.
Comparing those who developed incident tuberculosis and
those who did not, there were statistically significant differences in
the average monthly income of the head of household (456.3 and
661.9 reais); average BMI (21.4 and 23.9 Kg/m2); and average
baseline CD4 count (275.2 and 456.7 cel/mm3) (data not shown).
Table 3 shows the final Cox multivariate regression model for
the association between exposures and incidence of TB stratified
by use of HAART (time-dependent). Remained in the model, by
significantly increasing the risk of TB: indication for but non-
implementation of treatment for LTBI and TST not tested;
baseline CD4 cell count ,200 cell/mm3; anemia (and not testing
for it); previous treatment for TB; BMI ,18.5 kg/m2 and being
illiterate. The proportional hazards test was respected in the
multivariate model (p = 0.8294). Table 4 shows that among the
subgroup with a history of TB treatment, when compared to those
with a TST,5 mm, patients with a TST$5 mm who didn’t
receive preventive treatment had a higher risk of TB (HR = 6.70)
than patients with TST$5 mm who receive preventive treatment
for TB (HR = 1.67). When we compare only those who tested
positive among those with previous treatment, those who did not
receive treatment had three times the risk for TB than those who
did not receive treatment (HR: 3.36, 95%–CI: 0.37–30.5) though
the difference was not statistically significant.
Smoking did not remain in the final model. When we examined
the risk of tuberculosis associated with smoking separately for
PLHIV according reported use of drugs, there was no increase in
risk of TB associated with smoking in those who did not use drugs,
and a doubling of the risk of tuberculosis with smoking (current
and past) in those who reported using drugs, but this did not reach
statistical significance. Use of drugs was more frequent in ex-
smokers than in never smokers and in current smokers than in ex-
smokers (data not shown).
Discussion
The incidence rate of tuberculosis was 2.8 per 100 person-years.
Risk of TB was higher in those with markers of TB infection
(positive TST but no treatment of LTBI, and TB treatment in the
past); those with inadequate control of HIV infection (low CD4
count; non-use of HAART), those with poor general health (low
BMI; anemia) and illiterate. The probability of survival free of
tuberculosis after an individual average 2.5 years of follow up was
91%. This is consistent with a study in Brazil which followed 281
patients with 13 incident cases in 60 months [15] and higher than
a study in South Africa which followed 346 with 27 incident cases
in 5 years [16]. This may have resulted from good access to free at
the point of use supply of antiretroviral treatment in Brazil, which
Figure 1. Kaplan-Meier probability of TB-free Survival.
doi:10.1371/journal.pone.0063916.g001
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has been shown to be a protective factor for TB [17,18]. 79.3% of
patients in our study reported use of HAART on entry into the
cohort. The incidence rate of 2.8 per 100 person/years is
intermediate between those in Africa [19–21], and those in
developed countries [22,23] and parts of Asia [18]. A much
smaller Brazilian study [15], found a lower rate; there were no
other Brazilian studies.
In addition to the often studied clinical and laboratory factors,
we also investigated whether socioeconomic and lifestyle factors
are associated with higher risk of TB in PLHIV. Although average
income of individuals with incident TB was lower than in
individuals without TB (p = 0.000), only illiteracy of the socio
economic factors studies remained in the final model, doubling the
risk of developing TB. Poverty and illiteracy were closely
associated [24]. The main lifestyle variables in this analysis were
smoking and use of recreational drugs. Smoking has not been
sufficiently studied as a risk factor for incident tuberculosis in
PLHIV, although there is clear evidence of an effect of smoking in
the general population: a meta-analysis of this association in HIV
negative people found that current smokers were 2.6 and former
smokers 1.6 more likely to develop pulmonary TB when compared
with never smokers [25], and smoking was associated with higher
risk of progression from LTBI infection to disease [26], of
recurrence of TB [27] and of mortality from TB [28].Smoking is
often more common in PLHIV than in the general population
[29]. Miguez-Burbano and colleagues [30] in the United States
Table 1. Frequencies and bivariate analysis of the association between demographic, socioeconomic and lifestyle factors with the
development of tuberculosis in people living with HIV, Recife, 2010.
N (%) HR (CI 95%) p
Test of proportional-hazards
assumption (p)
Demographic variables
Sex
Female 809 (39.1) 1.0
Male 1260 (60.9) 1.53 (1.07–2.17) 0.019 0.4478
Age group (years)
18–39 1062 (51.3) 1.0
$40 1007 (48.7) 0.89 (0.65–1.23) 0.496 0.2776
Socioeconomic variables
Social support
Living with family 1667 (80.8) 1.0
Living alone or in shelters 395 (19.2) 0.95 (0.63–1.44) 0.817 0.7090
City of residence 0.1893
Recife 841 (40.9) 1.0
Metropolitan region 916 (44.6) 0.81 (0.57–1.15) 0.244 0.0710
Other cities 298 (14.5) 0.85 (0.51–1.40) 0.515 0.3988
Literacy
Yes 1832 (88.8) 1.0
No 232 (11.2) 1.95 (1.29–2.94) 0.001 0.5928
Head of the family monthly income
$1 minimum wage 1378 (68.7) 1.0
,1 minimum wage 627 (31.3) 1.28 (0.90–1.81) 0.168 0.7822
Variables related to lifestyle
Alchohol consumption
None or light drinker 1832 (88.6) 1.0
Heavy drinker 235 (11.4) 0.94 (0.56–1.57) 0.805 0.5791
Smoking status 0.3675
Never 933 (45.1) 1.0
Former 537 (25.9) 1.17 (0.77–1.77) 0.446 0.9909
Current 599 (29.0) 1.53 (1.05–2.23) 0.026 0.2029
Smoking status
Never or former 1470 (71.0) 1,0
Current 599 (29.0) 1.44 (1.03–2.02) 0.034 0.1563
Recreational drugs use
Never 1501 (72.6) 1.0
Past or current 568 (27.4) 1.82 (1.31–2.53) 0.000 0.0968
doi:10.1371/journal.pone.0063916.t001
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reported a doubling of risk of development of TB in PLHIV who
smoked for 20 years or more.
In our study smoking did not remain independently associated
with incident TB in multivariate analysis in spite of the fact that
remarkably high prevalences of reported past (25.9%) and current
(29.0%) smoking were found. The absence of an effect of smoking
was unexpected.
The use of recreational drugs, though statistically significant in
the bivariate analysis, was excluded from the multivariate model
due to the absence of proportionality in this step, limiting the
investigation of its effect on incident tuberculosis.
In the literature it has been reported that recreational drugs
users are at a higher risk of TB disease independently of HIV
status [5,31]. TB outbreaks among non-injecting drugs users have
been identified and thought to be due both a consequence of
sharing drug equipment and poor ventilation [31,32].
Tuberculosis and HIV infection are known to be associated with
malnutrition [33], although the picture is more complex, as with
the prevalence of overweight/obesity increases among PLHIV
receiving HAART [34]. Even so body mass index ,18.5 kg/m2,
has been reported to be associated with TB in PLHIV [35] and
this was consistent with our findings. Anemia, as well as low BMI,
is common in chronic infections and can reach levels of up to 95%
prevalence in individuals infected with HIV, and is also is
associated with progression to AIDS and increased risk of death
[36]. In our study 22.9% of patients were not tested for anemia,
but of those who were, 40% were anemic, and both having anemia
and not having a test were associated with TB, consistently with
the literature [37]. In patients diagnosed with tuberculosis in
Korea, most of the anemia (64.5%) reverted during or after
therapy for TB [38].
The use of HAART is associated with a marked increase in
survival of PLHIV, as it improves immune condition and
decreases risk of opportunistic infection: HAART has been
reported to reduce the proportion of people with HIV that
develop TB by more than 80% [19] in spite of the fact that PLHIV
receiving HAART have a longer life expectancy (and therefore a
longer number of years at risk of developing tuberculosis [18]. A
recent systematic review and meta-analysis of the impact of
HAART on incidence of tuberculosis in PLHIV in developing
countries show a reduction in TB incidence across all baseline
CD4 counts [39]. In our study, the non-use of HAART was
associated with an increased risk of incident TB (HR = 2.9),
consistent with the literature [13,19,20,22].
Table 2. Frequencies and bivariate analysis of the association between clinical, laboratory and treatment HIV-related factors,
tuberculosis and health services factors with the development of tuberculosis in people living with HIV, Recife, 2010.
N (%) HR (CI 95%) p
Test of proportional-hazards
assumption (p)
Clinical, laboratory and treatment HIV-related variables
General health variables
BMI
$18.5 kg/m2 1869 (92.5) 1.0
,18.5 kg/m2 151 (7,5) 2.87 (1.87–4.42) 0.000 0.7917
Anemia 0.6060
No 954 (46.1) 1.0
Yes 642 (31.0) 3.75 (2.51–5.62) 0.000 0.3260
Missing 473 (22.9) 2.41 (1.50–3.87) 0.000 0.6671
HIV related variables
Antirretroviral treatment (baseline)
Yes 1635 (79.3) 1.0
No 428 (20.7) 1.13 (0.76–1.67) 0.545 0.0130
Antirretroviral treatment (time-dependent)
Yes – 1.0
No – 1.42 (0.95–2.13) 0.086 0.0216
CD4 cell count (baseline)
$200 cel/mm3 1430 (81.7) 1.0
,200 cel/mm3 321 (18.3) 4.50 (3.18–6.37) 0.000 0.5379
Tuberculosis and Health Services variables
Previous tuberculosis treatment
No 1582 (78.3) 1.0
Yes 439 (21.7) 2.45 (1.75–3.44) 0.000 0.9172
Indication for LTBI treatment 0.4595
No indication and no treatment 888 (42.9) 1.0 –
Indication and treatment 153 (7.4) 0.60 (0.21–1.70) 0.340 0.9233
Indication and no treatment 152 (7.4) 5.81 (3.65–9.23) 0.000 0.1145
Tuberculin test not performed 876 (42.3) 1.99 (1.34–2.95) 0.001 0.4950
doi:10.1371/journal.pone.0063916.t002
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Having a low CD4 count increased the incidence of TB by nine
fold in our study. This was higher than in most studies that looked
at effect of baseline CD4 count [16,22,40], but similar to that
found by Lawn et al [17], who, similar to our study, took into
account variations in CD4 count with time and therefore
estimated the effect of the CD4 count at the nearest time before
the TB occurrence.
There is consensus in the literature that the treatment of LTBI
reduces the risk of active TB in PLHIV [41–43]; this is the reason
for the WHO recommendation for testing and isoniazid preven-
tive therapy (IPT) for a minimum of six months [44]. In our study,
patients who had TST$5 mm but who did not receive treatment
had an almost tenfold increase in risk of incident TB (HR = 9.8);
whereas those treated had no increase in risk. Starting treatment of
TBLI for HIV infected patients in routine in Brazil remains the
decision of the attending physician [42,45]; in our study only half
of those identified with LTBI were treated. Equally concerning,
42% of all PLHIV in our study were not TST tested, contrary to
WHO [46] and the Ministry of Health in Brazil [8] recommen-
dations. Treatment of LTBI is not simple: it requires two visits for
testing (purified protein derivative inoculation and reading),
prescription of treatment and patient compliance with additional
medication, but evidence is overwhelming that it reduces the risk
of TB in PLHIV [13,47].
Thirty-eight percent of incident TB cases in our study reported
TB treatment in the past, a higher percentage than those found in
parts of Asia (22%) and the Ivory Coast (24%) [18,48]. Although
TB recurrence occurs more frequently in PLHIV [49] due to
immune depletion and consequent failure to contain the bacillus
[50], very few epidemiological studies included a history of past
TB in the risk factors model for incident TB in PLHIV: Seyler
et al [48] found an association and Lawn et al [16] found no
association; until recently there were no specific recommendations
for PLHIV with a history of TB. In our study, we found a doubling
of risk in those with a history of TB; although, among those with
previous tuberculosis treatment, there was a 3 fold increase in risk
of TB for those who are TST positive and did not receive a new
treatment after the TST when compared to those who received a
new treatment, this result did not reach statistical significance at
the 95% level, and requires further investigation. As in our study
the indication of the LTBI treatment was made by the assistant
physician, based on clinical judgment, indication bias cannot be
excluded. Only a randomized controlled trial could overcome this
limitation. A recent WHO guideline strongly recommend IPT for
at least six months, for those who are unlikely to have active TB,
including patients who had a previous TB treatment [51].
Our study had some limitations. This was an operational
research, following patients in a routine setting, so entry into the
follow up was not triggered by a common clinical criterion. This is
the main limitations of this study: the fact that risk onset is an
arbitrary point in time (date of recruitment), and not related to any
health/risk related event and therefore the sample is not
homogeneous in relation to several factors; so that there may be
some bias in the analysis of variables associated to the risk of TB.
Most tests and all interventions reflected the decision of the
clinician responsible for the routine treatment of these patients,
although additional data collection, including record reviews and
Table 3. Cox regression multivariate final model of the
association between studied variables and tuberculosis
development in people living with HIV, Recife, 2010.
Hazard ratio adjusted
(95% CI) p
Indication for LTBI treatment
No indication and no treatment 1.0
Indication and treatment 0.74 (0.22–2.44) 0.622
Indication and no treatment 7.90 (4.67–13.37) 0.000
Tuberculinic test not performed 1.63 (1.04–2.54) 0.032
CD4 cell count (baseline)
$200 cel/mm3 1.0
,200 cel/mm3 4.10 (2.77–6.08) 0.000
BMI
$18.5 kg/m2 1.0
,18.5 kg/m2 2.25 (1.38–3.67) 0.001
Anemia
No 1.0
Yes 2.93 (1.86–4.62) 0.000
Missing 2.07 (1.17–3.67) 0.012
Previous tuberculosis treatment
No 1.0
Yes 2.42 (1.65–3.55) 0.000
Literacy
Yes 1.0
No 1.74 (1.09–2.80) 0.021
Stratified by antiretroviral treatment.
Test of proportional-hazards assumption (p = 0.8294).
doi:10.1371/journal.pone.0063916.t003
Table 4. Cox regression multivariate model of the association between Indication for LTBI treatment and tuberculosis
development according to previous tuberculosis treatment in people living with HIV, Recife, 2010.
No Previous tuberculosis
treatment
Previous tuberculosis
treatment
Hazard ratio Adjusted* (95% CI) P value Hazard ratio Adjusted* (95% CI) P value
Indication for LTBI treatment
No indication and no treatment 1.0 1.0
Indication and treatment 0.59 (0.14–2.51) 0.473 1.67 (0.20–13.9) 0.637
Indication and no treatment 9.04 (4.95–16.5) 0.000 6.70 (2.15–20.8) 0.001
Tuberculinic test not performed 1.43 (0.81–2.51) 0.214 2.13 (0.93–4.85) 0.073
*Adjusted for CD4 cell count, Antirretroviral treatment, BMI, Anemia and literacy.
doi:10.1371/journal.pone.0063916.t004
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questionnaires, were initiated by the study. As a consequence,
diagnosis of TB was done by the attending physician, whether
bacteriologically confirmed or not. We are confident we included
all diagnosed cases of TB (because we searched in SINAN and TB
treatment is only released for patient registered in SINAN). We
exclude TB cases diagnosed within one month of entry into the
cohort to ensure that our cohort were tuberculosis free at the start
of the follow. To minimize misclassification in relation to loss of
follow-up and death, searches were conducted in the SIM-PE [9].
Our study had some specific strengths. The cohort of HIV infected
people was followed prospectively, allowing identification of
incident cases. We used HAART as time-dependent variables,
taking into account the time that each patient was at risk and
reflecting closely changes in use of antiretroviral therapy during
the follow-up. Including socioeconomic and lifestyle habits as
variables in the study allowed us to identify that the risk of incident
TB was higher among those illiterate (the well-known association
between poverty and tuberculosis continuing in PLHIV).
Conclusions
Our findings identify some action that can have a substantive
impact in reducing tuberculosis both at the individual and in
public health level. The findings of the increase in incident TB in
PLHIV drug users (and tobacco, although not significantly) are
new and offer the possibility of targeted interventions. The
interaction between tuberculosis and HIV control programs is
critical to the success of prevention of TB, and this should be
articulated in reference health services for HIV-infected individ-
uals.
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